Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 influenza in children

Viral Immunology

Volumn 27, Issue 8, 2014, Pages 375-382

  Co, Mary Dawn T ^a   Terajima, Masanori ^a   Thomas, Stephen J ^b   Jarman, Richard G ^b   Rungrojcharoenkit, Kamonthip ^c   Fernandez, Stefan ^c   Yoon, In Kyu ^c   Buddhari, Darunee ^c   Cruz, John ^a   Ennis, Francis A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY ANTIBODY; COMPLEMENT DEPENDENT LYTIC ANTIBODY; HEMAGGLUTINATION INHIBITING ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COMPLEMENT; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY TITER; ARTICLE; CHILD; COHORT ANALYSIS; COMPLEMENT DEPENDENT CYTOTOXICITY; DENGUE; DISEASE ASSOCIATION; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SEROCONVERSION; ADULT; AGED; BLOOD; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; MIDDLE AGED; PRESCHOOL CHILD; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84907514857     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2014.0061     Document Type: Article

References (30)

1. Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011;30:1081-1085.
2. DiLillo DJ, Tan GS, Palese P, and Ravetch JV. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 2014;20:143-151.
3. Epstein S, and Garcia M. Survey of human antibody responses to influenza M2 using a sensitive flow cytometric method. J Infect Dis 2014;209:975-977.
4. Epstein SL. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J Infect Dis 2006;193:49-53.
5. Forthal DN, Landucci G, Habis A, Zartarian M, Katz J, and Tilles JG. Measles virus-specific functional antibody responses and viremia during acute measles. J Infect Dis 1994; 169:1377-1380.
6. Grandea AG 3rd, Olsen OA, Cox TC, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A 2010;107:12658-12663.
7. Hashimoto G, Wright PF, and Karzon DT. Antibodydependent cell-mediated cytotoxicity against influenza virus-infected cells. J Infect Dis 1983;148:785-794.
8. Hicks JT, Ennis FA, Kim E, and Verbonitz M. The importance of an intact complement pathway in recovery from a primary viral infection: influenza in decomplemented and in C5-deficient mice. J Immunol 1978;121:1437-1445.
9. Hicks JT, Klutch MJ, Albrecht P, and Frank MM. Analysis of complement-dependent antibody-mediated lysis of target cells acutely infected with measles. J Immunol 1976;117: 208-215.
10. Hobson D, Curry RL, Beare AS, and Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972;70:767-777.
11. Huber M, and Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007;262:5-25.
12. Hughey PG, Compans RW, Zebedee SL, and Lamb RA. Expression of the influenza A virus M2 protein is restricted to apical surfaces of polarized epithelial cells. J Virol 1992;66:5542-5552.
13. Jegaskanda S, Job ER, Kramski M, et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013;190:1837-1848.
14. Jegaskanda S, Laurie KL, Amarasena TH, et al. Ageassociated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J Infect Dis 2013;208:1051-1061.
15. Kohl S, West MS, Prober CG, Sullender WM, Loo LS, and Arvin AM. Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J Infect Dis 1989;160:770-776.
16. Lamb RA, Zebedee SL, and Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985;40:627-633.
17. Ng S, Fang VJ, Ip DK, et al. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis 2013;208:1320-1324.
18. Nimmerjahn F, and Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010;236:265-275.
19. Potter CW, and Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35:69-75.
20. Qu Z, Liang X, Liu Y, Du J, Liu S, and Sun W. Hepatitis B virus sensitizes hepatocytes to complement-dependent cytotoxicity through downregulating CD59. Mol Immunol 2009;47:283-289.
21. Quinnan GV, Ennis FA, Tuazon CU, et al. Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine. Infect Immun 1980;30:362-369.
22. Reber A, and Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 2013;12:519-536.
23. Saha S, Chadha M, Al Mamun A, et al. Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia. Bull World Health Organ 2014;13:124412.
24. Tamura M, Webster RG, and Ennis FA. Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry. Virology 1991;182:211-219.
25. Tamura M, Webster RG, and Ennis FA. Neutralization and infection-enhancement epitopes of influenza A virus hemagglutinin. J Immunol 1993;151:1731-1738.
26. Cruz J, Co MD, Lee J-H, et al. Complement-dependent lysis of influenza a virus-infected cells by broadly crossreactive human monoclonal antibodies. J Virol 2012;86: 1901.
27. Vella S, Rocchi G, Resta S, Marcelli M, and De Felici A. Antibody reactive in antibody-dependent cell-mediated cytotoxicity following influenza virus vaccination. J Med Virol 1980;6:203-211.
28. Wrammert J, Koutsonanos D, Li GM, et al. Broadly crossreactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011;208:181-193.
29. Wrammert J, Smith K, Miller J, et al. Rapid cloning of high-Affinity human monoclonal antibodies against influenza virus. Nature 2008;453:667-671.
30. Yewdell JW, Frank E, and Gerhard W. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol 1981;126:1814-1819.